Aion Therapeutic Inc.

CNSX: AION


Canadian symbol: AION.CN
US symbol: ANTCF

Currency in CAD

Valuation Measures

Market Cap (intraday) 510.63M
Enterprise Value 311.55M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.50
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 7-6.84

Trading Information

Stock Price History

Beta (5Y Monthly) 0.74
52-Week Change 3100.00%
S&P500 52-Week Change 343.61%
52 Week High 30.1900
52 Week Low 30.0450
50-Day Moving Average 30.0983
200-Day Moving Average 30.1044

Share Statistics

Avg Vol (3 month) 3680.9k
Avg Vol (10 day) 3225.56k
Shares Outstanding 5118.14M
Implied Shares Outstanding 6N/A
Float 101.73M
% Held by Insiders 119.33%
% Held by Institutions 10.00%
Shares Short (Apr. 14, 2021) 4317.74k
Short Ratio (Apr. 14, 2021) 40.96
Short % of Float (Apr. 14, 2021) 4N/A
Short % of Shares Outstanding (Apr. 14, 2021) 40.27%
Shares Short (prior month Mar. 14, 2021) 4103.83k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr. 29, 2020
Most Recent Quarter (mrq)Jan. 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-25.59%
Return on Equity (ttm)-98.44%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -1.69M
Net Income Avi to Common (ttm)-3.31M
Diluted EPS (ttm)-0.0450
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)262.02k
Total Cash Per Share (mrq)0
Total Debt (mrq)580.18k
Total Debt/Equity (mrq)13.51
Current Ratio (mrq)1.02
Book Value Per Share (mrq)0.04

Cash Flow Statement

Operating Cash Flow (ttm)-1.13M
Levered Free Cash Flow (ttm)-2.26M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
AION.CN
Aion Therapeutic
2 months ago
AION.CN
Aion Therapeutic
2 months ago
AION.CN
Aion Therapeutic
2 months ago
AION.CN
Aion Therapeutic
8 months ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
19.33%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Aion Therapeutic Inc.


Aion Therapeutic Amends Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The A... Read More...

Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer

Dr. Fritsche has also been appointed Chief Science Officer of AI Pharma, a wholly-owned subsidiary of Aion TherapeuticToronto, Ontario--(Newsfile Corp. - September 10, 2020) - Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas... Read More...

Osoyoos Provides Board Update; Approves Name Change

Toronto, Ontario--(Newsfile Corp. - August 19, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to provide a Board of Directors ("Board of Directors" or the "Board") update following the recent election of the Company's new Board of Directors which includes the appointment of a new Executive Chair, Executiv... Read More...

Osoyoos Closes Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - August 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") is pleased to announce that the Company has closed its previously announced non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for g... Read More...

Osoyoos Announces Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - June 16, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that it proposes to complete a non-brokered private placement (the "Private Placement") of up to 20,000,000 units of the Company (the "Units"), at a price of $0.05 per Unit, for gross proceeds of up to $1,000,... Read More...

Osoyoos Provides Update on Annual and Special Meeting

Toronto, Ontario--(Newsfile Corp. - June 4, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has rescheduled its next annual and special meeting of shareholders (the "Annual Meeting") to be held on August 7, 2020.Management had initially scheduled its Annual Meeting to be held on July ... Read More...

Osoyoos Enters into Equipment Lease and Joint-Venture Agreement; Provides Corporate Update

Toronto, Ontario--(Newsfile Corp. - April 21, 2020) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announced today that the Company has entered into an equipment lease (the "Equipment Lease") and a joint-venture agreement (the "JV Agreement") with 2623942 Ontario Limited (the "Licensed Producer"). Furthermore, the Company... Read More...

Osoyoos Announces Debt Settlement

Toronto, Ontario--(Newsfile Corp. - September 23, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company") announces that it has entered into a debt settlement agreement with an arm's length creditor. The agreement reduces the Company's liabilities by $750,000 and improves the Company's financial position with respect to both... Read More...

Osoyoos Announces Termination of LOI with Anahit

Toronto, Ontario--(Newsfile Corp. - September 4, 2019) - Osoyoos Cannabis Inc. (CSE: OSO) ("Osoyoos" or the "Company) wishes to announce that its letter of intent with Anahit International Corp. ("Anahit") as previously announced on May 16, 2019 (the "LOI") has been terminated. Pursuant to the LOI, Osoyoos and Anahit were to complete a bu... Read More...

Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, July 26, 2019 -- Leo Acquisitions Corp. (LEQ-H.V) (β€œLeo” or the β€œCompany”) and CBx Brands Inc. (β€œCBx”) are pleased to announce that they have entered into a letter of intent (the β€œLOI”), dated July 10, 2019, pursuant to which the Company and ... Read More...
Coming Soon.

Delayed data (1h)


Share this page